deramiocel

Cell therapy

Also known as CAP-1002

Filedunder review

Evidence outlook · regulatory review

Duchenne Muscular Dystrophy: application under FDA review, decision date 2026-11-22

PDUFA target action date set for deramiocel BLA (2026-08-22). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

Latest reported trial: HOPE-3 (NCT05126758) · Phase 3 · met primary endpoint · grade pending

Also in development:Heart Failure · Phase 2

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Duchenne Muscular Dystrophy
Phase 2 (6)
Duchenne Muscular Dystrophy
NCT04428476 · Capricor Inc.
2020-08-05 – 2027-03 · Duchenne Muscular Dystrophy
What this study did
NCT03406780 · Capricor Inc.
2018-04-04 – 2020-03-10 · Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn
What this study did
NCT06304064 · Capricor Inc.
2018-06-21 – 2019-03-06 · Duchenne Muscular Dystrophy
What this study did
NCT02485938 · Capricor Inc.
2016-01-07 – 2017-09-14 · Duchenne Muscular Dystrophy, Cardiomyopathy
What this study did
Heart Failure
Other / comorbidity
NCT04623671 · Capricor Inc.
2020-11-15 – 2022-02-04 · Covid19
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT01458405 · Capricor Inc.
2012-11-13 – 2019-02-28 · Myocardial Infarction
What this study did
Phase 1 (2)
Heart Failure
NCT02293603 · Capricor Inc.
2014-11 – 2020-04 · Dilated Cardiomyopathy (DCM), Ischemic Cardiomyopathy, Nonischemic Cardiomyopathy, Heart Failure
What this study did
Other / comorbidity
NCT03145298 · Cedars-Sinai Medical Center
2017-10-01 – 2023-03-31 · Pulmonary Arterial Hypertension (PAH)
What this study did

Competitive landscape

7 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Duchenne Muscular Dystrophy: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Deramiocel: this drugPhase 3Cell therapyCardiac cell therapynot yet gradedNo reviewed efficacy summary in this indication
GivinostatApprovedSmall moleculeHDACReliable signal
NCT02851797: Mean Change From Baseline in 4 Standard Stairs (4SC) Climb After 18 Months of Treatment (Baseline and 18 months): Givinostat 1.27 seconds (Standard Error 0.04) | Placebo 1.48 seconds (Standard Error 0.058)
RGX-202Phase 2/3Gene therapy / editingDystrophin (microdystrophin transgene)not yet gradedNo reviewed efficacy summary in this indication
Delpacibart ZotadirsenPhase 2RNA / oligonucleotideDMD exon 44not yet gradedNo reviewed efficacy summary in this indication
BampidirsenPhase 1/2RNA / oligonucleotideDMD exon 53not yet gradedNo reviewed efficacy summary in this indication
Nivudirsen (BMN 351)Phase 1/2RNA / oligonucleotideDMD exon 51not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(7)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

22 November 2026FDA action datePDUFA extended to 22 November 2026 for deramiocel
US, FDA · Capricor Therapeutics · Source ↗

Recent

22 August 2026FDA action datePDUFA target action date set for deramiocel BLA
US, FDA · Source ↗
10 March 2026Filing acceptedFDA lifts CRL and resumes review of deramiocel BLA
US, FDA · Capricor Therapeutics · Source ↗
3 December 2025Topline resultHOPE-3 Phase 3 meets primary endpoint
Capricor Therapeutics · Source ↗
31 August 2025FDA action datePDUFA target date set for deramiocel
US, FDA · Source ↗
11 July 2025Complete response letterFDA issues a complete response letter for the deramiocel BLA
US, FDA · Capricor Therapeutics · Source ↗
4 March 2025Priority reviewFDA grants Priority Review to deramiocel BLA
US, FDA · Source ↗